We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
-9.72%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$6.67B
AUM Growth
-$658M
Cap. Flow
+$79.2M
Cap. Flow %
1.19%
Top 10 Hldgs %
57.1%
Holding
295
New
64
Increased
76
Reduced
63
Closed
70

Top Buys

Rank Stock Value
1
FRPT icon
Freshpet
FRPT
+$87.7M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$59.2M
3
STAA icon
STAAR Surgical
STAA
+$42.7M
4
KDP icon
Keurig Dr Pepper
KDP
+$35.7M
5
SNN icon
Smith & Nephew
SNN
+$34.1M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$81.1M
2
NARI
Inari Medical, Inc. Common Stock
NARI
+$79.9M
3
GSK icon
GSK
GSK
+$73.2M
4
HUM icon
Humana
HUM
+$69.2M
5
BUD icon
AB InBev
BUD
+$68M

Sector Composition

Rank Sector Weight
1 Healthcare 35.45%
2 Consumer Discretionary 6.85%
3 Consumer Staples 5.47%
4 Technology 5.39%
5 Communication Services 1.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AZN icon
151
AstraZeneca
AZN
$250B
$1.76M 0.03%
12,000
-38,000
-76% -$5.5M
ENLV icon
152
Enlivex Ltd
ENLV
$33.3M
$1.73M 0.03%
118,795
-28,405
-19% -$472K
INTS icon
153
Intensity Therapeutics
INTS
$11.5M
$1.72M 0.03%
34,902
-10,173
-23% -$566K
BJRI icon
154
BJ's Restaurants
BJRI
$1.49B
$1.71M 0.03%
50,000
-300,000
-86% -$10.6M
PMN icon
155
ProMIS Neurosciences
PMN
$120M
$1.62M 0.02%
93,393
-7,006
-7% -$149K
CRBP icon
156
Corbus Pharmaceuticals
CRBP
$180M
$1.33M 0.02%
250,000
+14,000
+6% +$124K
AXDX
157
DELISTED
Accelerate Diagnostics
AXDX
$1.32M 0.02%
1,879,227
-198,773
-10% -$227K
KAPA
158
Kairos Pharma
KAPA
$8.35M
$1.31M 0.02%
+1,404,000
New +$1.8M
MBRX icon
159
Moleculin Biotech
MBRX
$2.72M
$1.22M 0.02%
50,000
+37,297
+294% +$1.25M
OXBR icon
160
Oxbridge Re Holdings
OXBR
$10.8M
$1.18M 0.02%
+622,165
New +$2.37M
KMX icon
161
CarMax
KMX
$8.24B
$1.17M 0.02%
+14,980
New +$1.2M
WKSP icon
162
Worksport
WKSP
$10.9M
$1.15M 0.02%
+360,501
New +$2.63M
CVNA icon
163
Carvana
CVNA
$75.1B
$1.06M 0.02%
+25,275
New +$1.12M
ICU icon
164
SeaStar Medical
ICU
$12.2M
$1.02M 0.02%
+61,324
New +$1.15M
TRU icon
165
TransUnion
TRU
$15.2B
$996K 0.01%
+12,000
New +$1.1M
PTN
166
Palatin Technologies
PTN
$14M
$974K 0.01%
33,432
-6,425
-16% -$299K
FDMT icon
167
4D Molecular Therapeutics
FDMT
$552M
$969K 0.01%
300,000
– –
BIO icon
168
Bio-Rad Laboratories Class A
BIO
$9.16B
$932K 0.01%
+3,827
New +$1.15M
ANY icon
169
Sphere 3D
ANY
$17.1M
$879K 0.01%
220,493
+3,093
+1% +$22.9K
BCLI
170
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$870K 0.01%
+690,666
New +$1.22M
COSM icon
171
Cosmos Holdings
COSM
$13.7M
$836K 0.01%
1,917,710
+1,168,884
+156% +$722K
CHRN
172
ChronoScale Holdings
CHRN
$2.94B
$823K 0.01%
136,159
+21,116
+18% +$174K
MTVA
173
MetaVia Inc
MTVA
$7.49M
$809K 0.01%
47,782
-18,458
-28% -$352K
NKTR icon
174
Nektar Therapeutics
NKTR
$2.48B
$704K 0.01%
69,067
+800
+1% +$10.5K
GOVX icon
175
GeoVax Labs
GOVX
$3.76M
$703K 0.01%
+26,515
New +$1.17M
5 6
7
8 9

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return
ACM
Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return
PI
PGGM Investments Zeist, Netherlands $5.7B AUM 17.05% 1-Year Est. Return

Armistice Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Armistice Capital held 295 positions worth $6.67B, down 9% from $7.33B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Armistice Capital's Q1 2025 filing shows 64 new, 76 increased, 63 reduced and 70 closed positions. Its largest new stake was Freshpet: 716,960 shares worth $59.6M. The largest sale was Vertex Pharmaceuticals, an estimated $81.1M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 39% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

  • Armistice Capital's largest Q1 2025 buy was Freshpet: 716,960 shares worth $59.6M.
  • Armistice Capital added most to Regeneron Pharmaceuticals in Q1 2025, an estimated $59.2M increase.
  • Armistice Capital's biggest Q1 2025 reduction was Vertex Pharmaceuticals, cutting an estimated $81.1M.
  • Armistice Capital fully exited Inari Medical, Inc. Common Stock in Q1 2025, selling an estimated $79.9M.
  • Armistice Capital's ten largest holdings make up 57% of its $6.67B portfolio in Q1 2025.
  • Armistice Capital opened 64 new positions and closed 70 in Q1 2025.
  • Armistice Capital's portfolio value fell 9% quarter-over-quarter to $6.67B.

Based on Armistice Capital's 13F filing for Q1 2025, filed 15 May 2025.